Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for CURV, NEO and DAKT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Wednesday, 11 January 2023 04:25 PM

Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / January 11, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CURV Shareholders Click Here: https://www.zlk.com/pslra-1/torrid-holdings-class-action-submission-form?prid=35536&wire=1
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35536&wire=1
DAKT Shareholders Click Here: https://www.zlk.com/pslra-1/daktronics-class-action-submission-form?prid=35536&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, January 11, 2023, Press release picture

Torrid Holdings Inc. (NYSE:CURV)

This lawsuit is on behalf of all persons who purchased Torrid common stock in or traceable to the Company's July 2021 initial public offering.
Lead Plaintiff Deadline : January 17, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/torrid-holdings-class-action-submission-form?prid=35536&wire=1

According to the filed complaint, (i) in the first half of 2021, Torrid had experienced a temporary surge in demand as a result of changed consumer behaviors in response to the COVID-19 pandemic and government stimulus and that such ephemeral demand trends had dissipated and were not internally projected to continue following the initial public offering ("IPO"); (ii) Torrid was suffering from severe supply chain disruptions caused by the emergence of the Delta variant of COVID-19, which had first emerged in May 2021; (iii) Torrid was running materially below historical inventory levels as a result of supply chain disruptions; (iv) as a result, Torrid did not have sufficient inventory to meet expected consumer demand for its fiscal third quarter of 2021; (v) as a result, late inventory arrival had materially impaired the Company from effectively matching consumer buying trends, creating an undisclosed risk of increased markdowns and promotional activities necessary to sell undesirable inventory; (vi) Torrid's Chief Financial Office planned to retire shortly after the IPO; and (vii) as a result of the above, representations made in the Company's registration statement regarding Torrid's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the IPO, and were materially false and misleading and lacked a reasonable factual basis.

NeoGenomics, Inc. (NASDAQ:NEO)

NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35536&wire=1

According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

Daktronics, Inc. (NASDAQ:DAKT)

DAKT Lawsuit on behalf of: investors who purchased March 10, 2022 - December 6, 2022
Lead Plaintiff Deadline : February 21, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/daktronics-class-action-submission-form?prid=35536&wire=1

According to the filed complaint, during the class period, Daktronics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing challenges that increased costs, including supply chain disruptions, that impacted Daktronics' ability to fund inventory levels and operations; (2) as a result, it was probable that some portion of the Company's deferred tax assets would not be realized; (3) as a result, Daktronics was reasonably likely to record a material valuation allowance to its deferred tax assets; (4) there were material weaknesses in the Company's internal controls over financial reporting related to income taxes; (5) the foregoing presented liquidity concerns and there was substantial doubt as to the Company's ability to continue as a going concern; and (6) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Class Action
Back to newsroom
Back to Newsroom
Share by: